Objective: To evaluate the clinical usefulness of the microbubble contrast agent SonoVue in enhancing high-intensity focused ultrasound (HIFU) for the treatment of adenomyosis.
Methods: A total of 102 patients with adenomyosis, assessed from August 2015 to April 2017, were randomly divided into 1-minute (A) and 10-minute (B) groups, respectively. In groups A and B, HIFU started 1 minute and 10 minutes, respectively, after SonoVue injection. All patients underwent a magnetic resonance imaging scan before and after HIFU treatment.
Results: The occurrence rates of massive gray scale change, nonperfused volume, and fractional ablation were similar in both groups (P > .05). Meanwhile, sonication time to massive gray scale change was reduced in group A compared with group B (P < .05). In addition, mean power, total energy, and energy efficiency factor were lower in group A than group B (all P < .05). The incidence rates of most perioperative and all postoperative adverse events were similar in both groups (P > .05). The incidence rates of pain in the treated region, leg pain, and sciatic or buttock pain during HIFU were substantially lower in group A than group B (P < .05).
Conclusions: Overall, starting HIFU sonication at 1 minute after SonoVue injection enhances HIFU ablation by cavitation and heating and is safe. Early massive gray scale change, lower total energy, and reduced mean power are potential safety factors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jum.14638 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Focused Ultrasound and Microbubble-Mediated Delivery of CRISPR-Cas9 Ribonucleoprotein to Human Induced Pluripotent Stem Cells.
Mol Ther
January 2025
Department of Biology, Concordia University, 7141 Sherbrooke St. W H4B 1R6, Montreal, Canada; Department of Physics, Concordia University, 7141 Sherbrooke St. W H4B 1R6, Montreal, Canada. Electronic address:
CRISPR-Cas9 ribonucleoproteins (RNPs) have been heavily considered for gene therapy due to their high on-target efficiency, rapid activity and lack of insertional mutagenesis relative to other CRISPR-Cas9 delivery formats. Genetic diseases such as hypertrophic cardiomyopathy currently lack effective treatment strategies and are prime targets for CRISPR-Cas9 gene editing technology. However, current in-vivo delivery strategies for Cas9 pose risks of unwanted immunogenic responses.
View Article and Find Full Text PDFUltrasound-Triggered Oxygen Release System for Accelerating Wound Healing of Diabetic Foot Ulcers.
Adv Healthc Mater
January 2025
Department of Pharmaceutics, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China.
Diabetic foot ulcer (DFU) is a common complication of chronic diabetes mellitus. Oxygen plays a critical role in the healing process of DFU wounds by promoting cell migration and neovascularization. However, clinical hyperbaric oxygen (HBO) therapy predominantly uses systemic oxygen administration, posing challenges in inadequate DFU local oxygen penetration and potential ectopic organs oxygen toxicity.
View Article and Find Full Text PDFA novel numerical approach to elucidate experimental scatter in portal pressure measurement using ultrasound contrast agent.
Proc Inst Mech Eng H
January 2025
Department of Medical Sciences & Technology, IIT Madras, Chennai, Tamil Nadu, India.
The use of ultrasound contrast agents (UCAs) for estimating portal pressure has recently gained attention due to its clinical promise, yet variability in acoustic amplitude poses challenges. UCAs contain microbubbles (1-10 µm in diameter), and understanding their acoustic response is essential to address this variability. However, systematic exploration of factors influencing microbubble behavior remains limited in current literature.
View Article and Find Full Text PDFMicrobubble-Protected Oncolytic Virotherapy Targeted by Sonoporation Induces Tumor Necrosis and T-Lymphocyte Infiltration in Humanized Mice Bearing Triple-Negative Breast Cancer.
Int J Mol Sci
December 2024
Department of Pharmacology & Toxicology, Cancer Center & Research Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Oncolytic virotherapy has shown great promise in mediating targeted tumor destruction through tumor-selective replication and induction of anti-tumor immunity; however, obstacles remain for virus candidates to reach the clinic. These include avoiding neutralizing antibodies, preventing stimulation of the adaptive immune response during intravenous administration, and inducing sufficient apoptosis and immune activation so that the body's defense can work to eradicate systemic disease. We have developed a co-formulation of oncolytic viruses (OVs) with Imagent lipid-encapsulated, perfluorocarbon microbubbles (MBs) to protect the OVs from the innate and adaptive immune system.
View Article and Find Full Text PDFMethods for Rapid Characterization of Tunable Microbubble Formulations.
Bioengineering (Basel)
December 2024
Department of Biomedical Engineering, Boston University, Boston, MA 02215, USA.
Article Synopsis
- To optimize microbubble formulations for clinical use, it is crucial to quickly measure their size distribution, concentration, and acoustic intensity for effective design iterations.
- A new method was developed to compare different microbubble formulations by using optical and acoustic techniques to gather important data on size, concentration, and scattering intensity.
- Modifications were made to an open-source ImageJ code for better analysis of microbubble images, and a high-throughput agarose phantom was created to evaluate the echogenicity of microbubble solutions, helping to identify necessary design adjustments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!